Lyvgen Biopharma Holdings Limited | ClinicalTrials HQ

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, Uveal Neoplasms, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, eye disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, hepatocellular carcinoma, liver disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, sarcoma, stomach disorder, uveal disorder, uveal melanoma	Active, not recruiting	Phase 1	2026-06-12		NCT05075993
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)	Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma	Active, not recruiting	Phase 2	2026-05-19		NCT06378177